Browse RND2

Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic vesicle, secretory vesicle, acrosome membrane Lipid-anchor Cytoplasmic side Note=Colocalizes with RACGAP1 in Golgi-derived proacrosomal vesicles and the acrosome.
Domain PF00071 Ras family
Function

May be specifically involved in neuronal and hepatic functions. Is a C3 toxin-insensitive member of the Rho subfamily (By similarity).

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0007409 axonogenesis
GO:0008361 regulation of cell size
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0016049 cell growth
GO:0022604 regulation of cell morphogenesis
GO:0030307 positive regulation of cell growth
GO:0031346 positive regulation of cell projection organization
GO:0032535 regulation of cellular component size
GO:0045666 positive regulation of neuron differentiation
GO:0045927 positive regulation of growth
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048668 collateral sprouting
GO:0048670 regulation of collateral sprouting
GO:0048672 positive regulation of collateral sprouting
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0051962 positive regulation of nervous system development
GO:0060560 developmental growth involved in morphogenesis
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0090066 regulation of anatomical structure size
Molecular Function GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
GO:0047485 protein N-terminus binding
Cellular Component GO:0001669 acrosomal vesicle
GO:0002080 acrosomal membrane
GO:0005769 early endosome
GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0097223 sperm part
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RND2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RND2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.91; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RND2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5970.233
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9120.246
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3830.608
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2580.457
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.350.679
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1460.888
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2530.646
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7190.416
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.310.735
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.3190.229
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.7720.221
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2640.172
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RND2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RND2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RND2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RND2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RND2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RND2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRND2
NameRho family GTPase 2
Aliases Rho7; RhoN; ARHN; ras homolog gene family, member N; CTD-3199J23.4; GTP-binding protein Rho7; rho-related GT ......
Chromosomal Location17q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RND2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.